By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Millipore said today that with the completion of its purchase by Merck KGaA, it is delivering a notice to holders of its 3.75 percent Convertible Senior Notes due 2026 that the effective date of the Make-Whole Fundamental Change was July 14, when the deal was completed.

The purchase's completion also triggered an increase in the conversion rate "applicable to notes surrendered for conversion during the Make-Whole Conversion period," Millipore said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.